88660dkk
2,3 %
Date:2024-04-26Time:16:59:56Latest report:Q4-2023List:Large CapTicker:NOVO B
Market Cap:3 958 669 mdkkEnterprise Value:3 956 187 mdkkNet Sales:232 261 mdkkEarnings:83 683 mdkkEmployees:0ISIN:DK0062498333

Ratios

10-year key figure history for Novo Nordisk turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Novo Nordisk with index and moving average MA50 and MA200.

Stockprice:886,60
MA50:872,71
MA200:723,67
Price/MA200:22,5 %
RSI (14):54,4
Price/MA50:1,6 %

Description

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Pharmaceuticals